Piramal Pharma Limited
PPLPHARMA · General/Diversified · NSE
₹147
Current Market Price
Fair Value (DCF)
₹169
Margin of Safety
+15.0%
Updated just now
YieldIQ Score
37/100
Piotroski F-Score
6/9
Economic Moat
None
Confidence
13%
ROE
112.2%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.19 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.0%
Return on capital employed
EV / EBITDA
14.6×
Enterprise multiple
Debt / EBITDA
2.9×
Leverage vs earnings
Interest Coverage
2.0×
EBIT covers interest
Current Ratio
1.54×
Short-term liquidity
Asset Turnover
0.58×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹146.61
Bear case
₹7.61
MoS -1826.5%
Base case
₹168.6
MoS +13.0%
Bull case
₹177.03
MoS +17.2%
Ratio Trends
PPLPHARMA · last 4 annual periods
ROE
1.1%
ROCE
12.7%
Operating Margin
—
Debt / Equity
0.60×
PE
180.8×
EV / EBITDA
12.3×
Historical Financials
PPLPHARMA · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹6472 Cr | ₹2164 Cr | ₹2552 Cr | ₹9061 Cr | +11.9% |
| EBITDA | ₹1260 Cr | ₹894 Cr | ₹1367 Cr | ₹1649 Cr | +9.4% |
| EBIT | — | ₹191 Cr | ₹330 Cr | — | +19.9% |
| PAT | ₹376 Cr | ₹50.1 Cr | ₹101 Cr | ₹91.1 Cr | -37.6% |
| EPS (diluted) | — | ₹0.42 | ₹0.77 | — | +22.4% |
| CFO | ₹766 Cr | ₹484 Cr | ₹1005 Cr | ₹892 Cr | +5.2% |
| CapEx | ₹-890 Cr | — | — | ₹-664 Cr | — |
| FCF | ₹-123 Cr | — | — | ₹228 Cr | — |
| Total Assets | ₹12.8K Cr | ₹14.5K Cr | ₹15.3K Cr | ₹15.7K Cr | +7.0% |
| Total Debt | ₹4128 Cr | ₹2121 Cr | ₹2075 Cr | ₹4856 Cr | +5.6% |
| Shareholders' Equity | ₹6697 Cr | ₹6774 Cr | ₹7911 Cr | ₹8125 Cr | +6.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
PPLPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| NEULANDLAB NEULANDLAB | — | — | Pending | 17.1% | — |
| GRANULES GRANULES | — | — | Pending | 13.5% | — |
| APLLTD APLLTD | — | — | Pending | 11.2% | — |
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹0.25/sh
Last payout
2025-07-16
₹0.14
Peak payout
₹0.14
Trailing yield
0.10%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Piramal Pharma Limited (PPLPHARMA.NS) trades at 146.61 vs a model fair value of 168.60, a gap of 15.0%. Piotroski F-score: 6/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of PPLPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for PPLPHARMA →
Compare
Head-to-head with peers
Compare PPLPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse PPLPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.